Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA GESTIÓN DE LA INVESTIGACIÓN EN SEVILLA · Oct 30, 2019

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with T2DM.
• • 2. Age: 18-75 years.
• • 3. Treatment with dapagliflozin or sitagliptin that started at least 6 months before the recruitment date.
• • 4. The patient must have at least two follow-up visits. The basal initial visit, where all the relevant information is collected and a second follow-up visit.
• • 5. The next information of the subjects should be available at the recruitment of the basal visit: Sex, age (years), date of diagnosis of T2DM, weight, height, systolic and diastolic blood pressure, body mass index (BMI: kg / m2), concomitant medication (antiHTA, statins, aspirin, etc.), glucose basal fasting (mg / dL), HbA1c (%) and estimated GFR by CKD-EPI (mL / min / 1.73m2).
• • 5. The patient must sign the informed consent to participate in the study.
• Exclusion Criteria:
• • 1. Impediment of the patient to give him informed consent.
• • 2. Patients diagnosed with Type 1 Diabetes.
• • 3. Women with gestational diabetes.

Trial Officials